Mohit Bansal, an analyst from Wells Fargo, maintained the Hold rating on Biogen (BIIB – Research Report). The associated price target ...

For lecanemab, scientists at AAIC highlighted the promise of the fluid tau marker MTBR-243 to track tangle load, and they ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.

Alzheimer disease research is yielding breakthroughs with blood tests and brain scans that can enhance early diagnosis, while ...

A recent announcement by Eli Lilly suggests that the company understands the economic conundrum some patients face. Per a ...

USF’s Memory Disorders Clinic fielding requests from patients and their families hoping that Donanemab can slow progressive brain disorder. Recently approved medication is showing success at ...

Another new drug, donanemab, is even more effective at slowing down the progression of Alzheimer’s disease. It was hailed as the “best ever” treatment for the disease by scientists after ...

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...

Since then, two other anti-amyloid antibodies, Biogen’s lecanemab and Eli Lily’s donanemab, have demonstrated an ability to slow cognitive decline in individuals with early Alzheimer’s ...